MX343863B - Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica. - Google Patents

Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.

Info

Publication number
MX343863B
MX343863B MX2013006669A MX2013006669A MX343863B MX 343863 B MX343863 B MX 343863B MX 2013006669 A MX2013006669 A MX 2013006669A MX 2013006669 A MX2013006669 A MX 2013006669A MX 343863 B MX343863 B MX 343863B
Authority
MX
Mexico
Prior art keywords
seq
nucleotide sequence
oligonucleotide
hybridising
under conditions
Prior art date
Application number
MX2013006669A
Other languages
English (en)
Other versions
MX2013006669A (es
Inventor
Vebø Heidi
Rudi Knut
Sekelja Monika
Original Assignee
Genetic Analysis As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Analysis As filed Critical Genetic Analysis As
Publication of MX2013006669A publication Critical patent/MX2013006669A/es
Publication of MX343863B publication Critical patent/MX343863B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un conjunto de sondas de oligonucleótido, caracterizado porque comprende: (a) un oligonucleótido que consiste de (ai) una secuencia de nucleótidos que se selecciona (SEC ID NO: 1), opcionalmente con hasta tres bases sustituidas y (SEC ID NO: 27), opcionalmente hasta con tres bases sustituidas, y (aii) 0 a 5 nucleótidos además de (ai) en donde el oligonucleótido (a) es capaz de hibridizar con la SEC ID NO: 27 o SEC ID NO: 1, respectivamente, bajo condiciones de alta severidad; (b) un oligonucleótido que consiste de (bi) una secuencia de nucleótidos que se selecciona de (SEC ID NO: 2), opcionalmente con hasta tres bases sustituidas y (SEC IC NO: 28), opcionalmente hasta con tres bases sustituidas, y (bii) 0 a 5 nucleótidos además de (bi) en donde el oligonucleótido (b) es capaz de hibridizar la SEX ID NO: 28 O SEC ID NO: 2, respectivamente, bajo condiciones de alta severidad; un oligonucleótido que consiste de (ci) una secuencia de nucleótidos que se selecciona de (SEC ID NO: 3),opcionalmente con hasta tres bases sustituidas, y (SEC ID NO: 29); opcionalmente hasta con tres bases sustituidas, y (cii) 0 a 5 nucleótidos además de (ci) en donde el oligonucleótido (c) es capaz de hibridizar a SEC ID NO: 29 o SEC ID NO: 3, respectivamente, bajo condiciones de alta severidad; (d) un oligonucleótido que consiste de (di) una secuencia de nucleótidos que se selecciona de (SEC ID NO; 4), opcionalmente con hasta tres bases sustituidas y (SEC ID NO: 30), opcionalmente hasta con tres bases sustituidas, y (dii) 0 a 5 nucleótidos además de (di) en donde el oligonucleótido (d) es capaz de hibridizar con la SEC ID NO: 30 o SEC ID NO: 4, respectivamente, bajo condiciones de alta severidad; y ( e) uno o más oligonucleótidos que consisten de (ei) una secuencia de nucleótidos que se selecciona de las mencionadas como las SEC ID NOS: 5 A 8 Y 31 a 34 en la tabla 1, opcionalmente hasta con tres bases sustituidas, y (eii) 0 a 5 nucleótidos además de (ei), en donde el oligonucleótido ( e) es capaz de hibridizar con la secuencia de nucleótidos complementaria a las SEC ID NOS: 5 A 8 y 31 a 34, respectivamente, bajo condiciones de alta severidad; y opcionalmente (f) uno o más oligonucleótidos que consisten de (fi) una secuencia de nucleótidos que se selecciona de las mencionadas como las SEC ID NOS: 9 a 26 y 35 a 52 en la tabla 2 y en la tabla 3, opcionalmente hasta con tres bases sustituidas, y (fii) 0 a 5 nucleótidos además de (fi), en donde el oligonucleótido (f) es capaz de hibridizar con la secuencia de nucleótidos complementaria a las SEC ID NOS: 9 a 26 y 35 a 52, respectivamente, bajo condiciones de alta severidad.
MX2013006669A 2010-12-16 2011-12-16 Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica. MX343863B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021399.9A GB201021399D0 (en) 2010-12-16 2010-12-16 Oligonucleotide probe set and methods of microbiota profiling
PCT/GB2011/052509 WO2012080754A2 (en) 2010-12-16 2011-12-16 Oligonucleotide probe set and methods of microbiota profiling

Publications (2)

Publication Number Publication Date
MX2013006669A MX2013006669A (es) 2013-11-04
MX343863B true MX343863B (es) 2016-11-25

Family

ID=43567352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006669A MX343863B (es) 2010-12-16 2011-12-16 Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.

Country Status (14)

Country Link
US (2) US9243297B2 (es)
EP (1) EP2652145B1 (es)
AU (1) AU2011342983B2 (es)
BR (1) BR112013015082A2 (es)
CA (1) CA2821884C (es)
DK (1) DK2652145T3 (es)
ES (1) ES2573133T3 (es)
GB (1) GB201021399D0 (es)
MX (1) MX343863B (es)
NZ (1) NZ612010A (es)
PL (1) PL2652145T3 (es)
RU (1) RU2605913C2 (es)
WO (1) WO2012080754A2 (es)
ZA (1) ZA201304546B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021399D0 (en) 2010-12-16 2011-01-26 Genetic Analysis As Oligonucleotide probe set and methods of microbiota profiling
US20150211053A1 (en) * 2012-08-01 2015-07-30 Bgi-Shenzhen Biomarkers for diabetes and usages thereof
US11003041B2 (en) * 2014-06-30 2021-05-11 View, Inc. Power management for electrochromic window networks
WO2016014822A1 (en) * 2014-07-25 2016-01-28 Ge Healthcare Uk Limited Screening and monitoring the progression of type 2 diabetes by the molecular identification of gut flora using fta as a faecal collection device
GB201505364D0 (en) * 2015-03-27 2015-05-13 Genetic Analysis As Method for determining gastrointestinal tract dysbiosis
CN105199948A (zh) * 2015-09-29 2015-12-30 窦晓鸣 大肠杆菌的快速检验试剂盒及检测方法
RU2601132C1 (ru) * 2015-11-27 2016-10-27 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Набор синтетических олигонуклеотидов для диагностики болезни крона и неспецифического язвенного колита путем выявления маркерных участков бактериальной днк методом полимеразной цепной реакции
JP7655693B2 (ja) 2016-05-23 2025-04-02 カリフォルニア インスティチュート オブ テクノロジー 神経変性障害を治療するための腸内微生物叢の制御
RU2630669C1 (ru) * 2016-07-21 2017-09-11 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ определения метилирования сайтов PuCGPy регуляторных областей генов-онкомаркеров колоректального рака методом GLAD-ПЦР-анализа и набор олигонуклеотидных праймеров и флуоресцентно-меченых зондов для осуществления указанного способа
GB201617519D0 (en) 2016-10-14 2016-11-30 Genetic Analysis As A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
EA032051B1 (ru) * 2017-03-22 2019-03-29 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Способ идентификации в микробиомах и отдельных бактериальных геномах композиции бактериальных генов, участвующих в синтезе и метаболизме различных нейроактивных соединений
EP3607096A1 (en) * 2017-04-03 2020-02-12 Bio-Me AS Microorganism detection methods
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
WO2018209398A1 (en) * 2017-05-17 2018-11-22 Microbio Pty Ltd Biomarkers and uses thereof
AU2018253466B2 (en) 2017-07-17 2019-03-28 smartDNA Pty Ltd Method of diagnosing a dysbiosis
US20210317508A1 (en) * 2017-08-01 2021-10-14 Axial Therapeutics, Inc. Methods and apparatus for determining risk of autism spectrum disorder
GB201712459D0 (en) 2017-08-02 2017-09-13 Norges Miljø-Og Biovitenskapelige Univ Treatment or prevention of gastrointestinal dysbiosis
RU2702229C1 (ru) * 2018-08-09 2019-10-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения атопического дерматита у детей пробиотическими препаратами с учетом результатов микробиологического исследования кала
GB201817889D0 (en) 2018-11-01 2018-12-19 Bio Me As Microorganism detection methods
TR201818373A2 (tr) * 2018-12-03 2020-06-22 T C Erciyes Ueniversitesi Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇
US20220259332A1 (en) * 2019-07-19 2022-08-18 Washington University Particle-based method for defining a gut microbiota in humans or other animal species

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267234A (en) 1978-03-17 1981-05-12 California Institute Of Technology Polyglutaraldehyde synthesis and protein bonding substrates
US4267235A (en) 1979-03-19 1981-05-12 California Institute Of Technology Polyglutaraldehyde microspheres
IL63220A (en) 1981-07-01 1985-09-29 Yeda Res & Dev Process for production of polyacrolein microspheres
US4717655A (en) 1982-08-30 1988-01-05 Becton, Dickinson And Company Method and apparatus for distinguishing multiple subpopulations of cells
US4677138A (en) 1983-10-19 1987-06-30 Yeda Research And Development Co., Ltd. High yield process for producing polyaldehyde microspheres
US5073498A (en) 1984-12-24 1991-12-17 Caribbean Microparticles Corporation Fluorescent alignment microbeads with broad excitation and emission spectra and its use
US4774189A (en) 1984-12-24 1988-09-27 Flow Cytometry Standards Corp. Fluorescent calibration microbeads simulating stained cells
US5194300A (en) 1987-07-15 1993-03-16 Cheung Sau W Methods of making fluorescent microspheres
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
FR2707658B1 (fr) 1993-07-12 1995-11-24 Prolabo Sa Latex fluorescent comportant au moins deux fluorochromes, procédé d'obtention et application dudit latex comme marqueur, notamment en biologie.
AU7398996A (en) 1995-10-11 1997-04-30 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US5786219A (en) 1996-10-28 1998-07-28 Molecular Probes, Inc. Microspheres with fluorescent spherical zones
GB9709728D0 (en) 1997-05-13 1997-07-02 Dynal As Single step method
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6632526B1 (en) 1997-10-14 2003-10-14 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
GB9807045D0 (en) 1998-04-01 1998-06-03 Rudi Knut Nucleic acid detection method
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US6649414B1 (en) 1999-08-17 2003-11-18 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
ATE324588T1 (de) 1999-08-17 2006-05-15 Luminex Corp Verkapselung von fluoreszierenden partikeln
EP1212599A2 (en) 1999-08-30 2002-06-12 Illumina, Inc. Methods for improving signal detection from an array
GB0001450D0 (en) 2000-01-21 2000-03-08 Genpoint As Cell isolation method
CA2399908A1 (en) 2000-02-10 2001-08-16 Todd Dickinson Array of individual arrays as substrate for bead-based simultaneous processing of samples and manufacturing method therefor
CA2414618C (en) 2000-06-28 2009-11-03 Illumina, Inc. Composite arrays utilizing microspheres with a hybridization chamber
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
WO2004003511A2 (en) * 2002-07-01 2004-01-08 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
US7919277B2 (en) * 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
AT501919B1 (de) * 2005-06-14 2008-09-15 Erber Ag Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung
GB0601302D0 (en) 2006-01-23 2006-03-01 Semikhodskii Andrei Diagnostic methods and apparatus
KR100868760B1 (ko) * 2006-09-28 2008-11-17 삼성전자주식회사 그람 음성 및 양성 박테리아를 구별하기 위한 프라이머세트, 프로브 세트, 방법 및 키트
RU2010144789A (ru) * 2008-04-01 2012-05-10 Метаметрикс Клиникал Лэборетери (Us) Процесс и способ мониторинга желудочно-кишечной микрофлоры
US20100279882A1 (en) * 2009-05-01 2010-11-04 Mostafa Ronaghi Sequencing methods
US20120238468A1 (en) 2009-10-05 2012-09-20 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
GB2475226A (en) 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
US8288137B2 (en) * 2010-11-15 2012-10-16 E I Du Pont De Nemours And Company Recombinant Escherichia coli having enhanced acetyl-coenzyme a synthetase activity for producing glyerol and glycerol-derived products
GB201021399D0 (en) 2010-12-16 2011-01-26 Genetic Analysis As Oligonucleotide probe set and methods of microbiota profiling

Also Published As

Publication number Publication date
ZA201304546B (en) 2014-03-26
DK2652145T3 (en) 2016-06-13
NZ612010A (en) 2015-05-29
AU2011342983B2 (en) 2017-03-30
CA2821884A1 (en) 2012-06-21
BR112013015082A2 (pt) 2019-09-17
WO2012080754A2 (en) 2012-06-21
US20130303397A1 (en) 2013-11-14
US20160068891A1 (en) 2016-03-10
US9909191B2 (en) 2018-03-06
CA2821884C (en) 2022-07-05
AU2011342983A1 (en) 2013-07-04
PL2652145T3 (pl) 2016-09-30
RU2013132761A (ru) 2015-01-27
RU2605913C2 (ru) 2016-12-27
EP2652145A2 (en) 2013-10-23
MX2013006669A (es) 2013-11-04
EP2652145B1 (en) 2016-03-09
US9243297B2 (en) 2016-01-26
GB201021399D0 (en) 2011-01-26
ES2573133T3 (es) 2016-06-06
WO2012080754A3 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
MX2013006669A (es) Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.
NZ602473A (en) Method of diagnostic of obesity
BRPI0607753A2 (pt) método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
CA2798593A1 (en) Methods and kits for diagnosing colorectal cancer
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
GB2467704A (en) Methods of monitoring conditions by sequence analysis
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR DISEASE DIAGNOSIS
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2009115615A3 (en) Detection and prognosis of cervical cancer
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
NO20070949L (no) Transkriptomdiagnostikk i spytt
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
EP3070474A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
JP2012533322A5 (es)
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2010011683A3 (en) Methods for the cytological analysis of cervical cells
GB2451985A (en) Sepsis detection microarray
BRPI0811930B8 (pt) métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo
EP2957642A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
EP3839068A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2012006056A3 (en) Ccr6 as a biomarker of alzheimer's disease
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment

Legal Events

Date Code Title Description
FG Grant or registration